Page last updated: 2024-10-28

hydrochlorothiazide and Diffuse Parenchymal Lung Disease

hydrochlorothiazide has been researched along with Diffuse Parenchymal Lung Disease in 1 studies

Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.

Research Excerpts

ExcerptRelevanceReference
"The differential diagnosis of pulmonary disease should include drug toxicity, progression of the primary illness, and opportunistic infection."2.42Infiltrative lung disease due to noncytotoxic agents. ( Cooper, JA; Eggert, M; Lock, BJ, 2004)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lock, BJ1
Eggert, M1
Cooper, JA1

Reviews

1 review available for hydrochlorothiazide and Diffuse Parenchymal Lung Disease

ArticleYear
Infiltrative lung disease due to noncytotoxic agents.
    Clinics in chest medicine, 2004, Volume: 25, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Humans; Hydrochlorothiazide;

2004